PYXS Company Profile and Key Details

Q: Who are the executives of PYXS?

Mr. John L. Flavin M.B.A., MBA, Ph.D.Co-Founder & Independent ChairmanDr. Jan Pinkas Ph.D.Chief Scientific OfficerMs. Martina Molsbergen B.S.Interim Chief Bus. OfficerDr. Lara S. Sullivan M.D., MBAChief Executive Officer, Pres & DirectorDr. Jay M. Feingold M.D., Ph.D.Chief Medical OfficerDr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program ManagementMr. Jitendra WadhaneChief Accounting Officer, Senior Vice President of Fin. & Corporation ControllerMs. Pamela Yanchik Connealy M.B.A.Chief Financial Officer & Chief Operating OfficerDr. Balu N. Balasubramanian Ph.D.Advisor

NASDAQ : PYXS

Pyxis Oncology

$1.62

-0.05-2.99%

At Close 4:00 PM

55.38

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pyxis Oncology, Inc. (PYXS) stock declined over -2.99%, trading at $1.62 on NASDAQ, down from the previous close of $1.67. The stock opened at $1.67, fluctuating between $1.58 and $1.70 in the recent session.

Stock Snapshot

1.67

Prev. Close

100.87M

Market Cap

1.58

Day Low

-1.03

P/E Ratio

-1.58

EPS (TTM)

-1.73

Cash Flow per Share

1.67

Open

62.26M

Number of Shares

1.695

Day High

65.8%

Free Float in %

2.81

Book Value

206.87K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 17, 2026	1.67	1.68	1.58	1.62	207.23K
Mar 16, 2026	1.57	1.69	1.54	1.67	592.59K
Mar 13, 2026	1.54	1.60	1.51	1.54	227.09K
Mar 12, 2026	1.54	1.57	1.46	1.53	207.81K
Mar 11, 2026	1.56	1.57	1.48	1.56	175.62K
Mar 10, 2026	1.47	1.61	1.47	1.55	751.96K
Mar 09, 2026	1.37	1.51	1.35	1.50	452.82K
Mar 06, 2026	1.36	1.39	1.33	1.37	272.26K
Mar 03, 2026	1.42	1.48	1.40	1.43	156.4K
Mar 02, 2026	1.40	1.48	1.39	1.47	461.35K
Feb 27, 2026	1.49	1.52	1.46	1.47	137.11K
Feb 26, 2026	1.52	1.54	1.44	1.52	172.61K
Feb 25, 2026	1.50	1.54	1.46	1.52	215.91K
Feb 24, 2026	1.45	1.52	1.43	1.48	343.22K
Feb 23, 2026	1.40	1.46	1.39	1.45	248.31K
Feb 20, 2026	1.52	1.54	1.41	1.42	238.14K
Feb 19, 2026	1.37	1.54	1.34	1.53	566.94K
Feb 18, 2026	1.33	1.39	1.33	1.37	287.57K
Feb 17, 2026	1.30	1.35	1.27	1.33	350.9K
Feb 13, 2026	1.34	1.39	1.30	1.30	190.84K

Contact Details

Boston, MA 02140

United States

https://www.pyxisoncology.com 617 221 9059

About Company

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Stock Peers

REGN

2.14+0.28%

Regeneron Pharmaceuticals, Inc.$759.05 ARGX

2.73+0.39%

argenx SE$706.03 UTHR

5.72001+1.07%

United Therapeutics Corporation$540.02 VRTX

-3.61-0.77%

Vertex Pharmaceuticals Incorporated$462.49 MDGL

2.35+0.53%

Madrigal Pharmaceuticals, Inc.$443.18 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.51+0.47%

Alnylam Pharmaceuticals, Inc.$320.42 PRAX

-1.62-0.53%

Praxis Precision Medicines, Inc.$303.38 KRYS

6.17+2.47%

Krystal Biotech, Inc.$256.33 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Pyxis Oncology, Inc. (NASDAQ:PYXS) closed at $1.62 USD, losing -$0.05 (-2.99%) from the previous close of $1.67. The stock is currently mid-range between its 52-week high and low $0.83 and $5.55. With a market capitalization of about $100.87 million, Pyxis Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 994.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Pyxis Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas Civik, the company employs approximately 44 people and listed since October 08, 2021. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 4.94%, SMA50 -5.69%, SMA200 -27.17%). The stock’s 14-day RSI is 47.85 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -72.61% below its high and over 82.43% above its low. Average 10-day trading volume of 373.59 thousand shares is below the 3-month average of 1.01 million, indicating normal recent market interest.

Valuation Metrics

Pyxis Oncology, Inc. trades at a P/E ratio of -1.05, slightly below the S&P 500 average, with a price-to-sales ratio of 35.88 and a price-to-book ratio of 1.48 suggesting the stock is closer to book value. The P/FCF stands at -1.4, also below market averages.

Dividend & Fair Value

Pyxis Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.06. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Pyxis Oncology, Inc. generated EPS of -$1.59 over the past year. Five-year average earnings growth is -74.92%. Wall Street analysts project EPS growth of -0.91% annually over the next five years. The latest quarter delivered EPS of -$0.35. The next quarter is forecast at -$0.34. Next year's EPS is expected at $22.06. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $5.00. The high target offers 393.83% upside. The low target suggests 208.64% downside. The mean target is $6.62. This offers 308.64% upside. Pyxis Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by -2.78%. The prior quarter beat by -16.67%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in August 16, 2024.

Shareholding & Insider Activity

Pyxis Oncology, Inc. has 62.02 million shares outstanding. The public float is 41.18 million shares, elevated short interest at 8.46% of float. This equals 4.33 million shares. The short ratio is 10.29 days. Institutional investors hold 44.03% of the float. Insiders own 23.39%. PFIZER INC holds 5.95 million shares, Sullivan Lara has 2.40 million shares and Cormorant Asset Management, LP has 1.12 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Pyxis Oncology has not generated any revenue. Returns are negative, with ROA at -42.47% and ROE at -58.70%.
On valuation metrics, Pyxis Oncology trades at a P/E of -1.05, P/S of 35.88 and P/B of 1.48. The current ratio is 4.29 and quick ratio is 4.29. Debt-to-equity is 0.28, supported by a cash flow-to-debt ratio of -3.79.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pyxis Oncology posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $2.00M (margin 0.00%). Operating income was - $82.20M (margin 0.0%). Net income was- $73.79M (EPS - $1.85).
The company ended the quarter with $120.77M in cash and short-term investments, a total debt of $21.33M, and net debt of $10.20M. Total assets were $173.73M, with equity of $125.70M. Financials further reflected weakness, with operating cash flow of - $70.71M, free cash flow of - $77.44M, and capital expenditures of - $6.73M.

Price Forecast & Outlook

Our AI price prediction model suggests that Pyxis Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.56%, with price expected at $1.71 by March 31, 2026, within a range of $1.65 to $1.78 3-Month Outlook: Projected fall of -62.96%, reaching $0.60 by June 15, 2026, with a range of $0.27 to $0.68. 1-Year Outlook: Projected gain of 404.94%, with price at $8.18 by March 17, 2027, within a range of $0.83 to $14.81.

Key Takeaways

Pyxis Oncology, Inc. (NASDAQ:PYXS) shares are up 44.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pyxis Oncology, Inc. trading at a premium to the broader market with a P/E of -1.05. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $8.84, suggesting 445.68% upside. Our AI forecast model points to short-term strength (5.56% over two weeks), a medium-term fall (-62.96% over three months), and a longer-term gain (404.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pyxis Oncology, Inc. (PYXS) stock price?

Pyxis Oncology, Inc. (NASDAQ: PYXS) stock price is $1.62 in the last trading session. During the trading session, PYXS stock reached the peak price of $1.70 while $1.58 was the lowest point it dropped to. The percentage change in PYXS stock occurred in the recent session was -2.99% while the dollar amount for the price change in PYXS stock was - $0.05.

PYXS's industry and sector of operation?

The NASDAQ listed PYXS is part of Biotechnology industry that operates in the broader Healthcare sector. Pyxis Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PYXS?

Mr. John L. Flavin M.B.A., MBA, Ph.D.
Co-Founder & Independent Chairman
Dr. Jan Pinkas Ph.D.
Chief Scientific Officer
Ms. Martina Molsbergen B.S.
Interim Chief Bus. Officer
Dr. Lara S. Sullivan M.D., MBA
Chief Executive Officer, Pres & Director
Dr. Jay M. Feingold M.D., Ph.D.
Chief Medical Officer
Dr. Charles T. Gombar Ph.D.
Senior Vice President of Portfolio & Program Management
Mr. Jitendra Wadhane
Chief Accounting Officer, Senior Vice President of Fin. & Corporation Controller
Ms. Pamela Yanchik Connealy M.B.A.
Chief Financial Officer & Chief Operating Officer
Dr. Balu N. Balasubramanian Ph.D.
Advisor

How PYXS did perform over past 52-week?

PYXS's closing price is 94.48% higher than its 52-week low of $0.83 where as its distance from 52-week high of $5.55 is -70.81%.

How many employees does PYXS have?

Number of PYXS employees currently stands at 44.

Link for PYXS official website?

Official Website of PYXS is: https://www.pyxisoncology.com

How do I contact PYXS?

PYXS could be contacted at phone 617 221 9059 and can also be accessed through its website. PYXS operates from 35 Cambridgepark Drive, Boston, MA 02140, United States.

How many shares of PYXS are traded daily?

PYXS stock volume for the day was 206.87K shares. The average number of PYXS shares traded daily for last 3 months was 994.41K.

What is the market cap of PYXS currently?

The market value of PYXS currently stands at $100.87M with its latest stock price at $1.62 and 62.26M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	44
Beta	1.46
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PYXS Company Profile and Key Details

Pyxis Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook